Ocular inoculation with H5N1 proves fatal in ferrets – University of Minnesota Twin Cities

iStock

Patients who received one or more COVID-19 vaccine doses after acute coronary syndrome (ACS) had similar rates of all-cause death, heart attack, stroke, urgent coronary revascularization, major cardiovascular events, and hospitalization for chest pain, heart failure, and respiratory infections as their unvaccinated peers, according to a secondaryanalysis of a randomized clinical trial.

The research was published inJAMA Network Open.

An international team led by researchers from Hospital Israelita Albert Einstein in Sao Paulo, Brazil, analyzed results from the Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes trial.

The trial evaluated the effectiveness of the influenza vaccine post-ACS from July 2019 to November 2020, while the secondary analysis compared the rate of cardiopulmonary events in patients who received at least one dose of COVID-19 vaccine in Brazil with that of unvaccinated participants. Patients were not randomized to the COVID vaccine in the secondary analysis.

In this secondary analysis of a randomized clinical trial, patients who received at least 1 COVID-19 vaccine dose after ACS had similar rates of the primary composite end point and MACE compared with unvaccinated patients.

Of 1,801 patients (median age, 56.7 years; 30.3% women), 16.2% had a history of heart attack, and 35.7% smoked. In total, 1,665 patients did not have cardiopulmonary events in the first 90 days, of whom 50.2% had received at least one COVID-19 vaccine dose. Most (63.9%) received at least one Oxford/AstraZeneca dose during follow-up.

In the 90-day event-free follow-up analysis of unvaccinated individuals, the rate of all-cause death, heart attack, stroke, urgent coronary revascularization, major cardiovascular events, and hospitalization for chest pain, heart failure, and respiratory infections per 100 patient-years was 9.37, versus 4.81 for vaccinated patients (adjusted hazard ratio [aHR], 0.41).

Vaccination didn't significantly lower the rate ofMACE (aHR, 0.32), all-cause death (aHR, 0.29), or cardiovascular death (aHR, 0.42).

"In this secondary analysis of a randomized clinical trial, patients who received at least 1 COVID-19 vaccine dose after ACS had similar rates of the primary composite end point and MACE compared with unvaccinated patients," the researchers wrote. "However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination."

Read the original post:

Ocular inoculation with H5N1 proves fatal in ferrets - University of Minnesota Twin Cities